AI is transforming biotechnology, as evidenced by significant investments like CytoReason's $80 million funding from Nvidia and Pfizer. This integration enhances drug discovery, protein engineering, and diagnostics while raising intellectual property challenges. Issues include determining inventorship, balancing patent disclosure with trade secrets, and ensuring compliance with legal requirements. As AI’s influence grows, strategic planning in patenting and protecting innovations becomes essential for success in this evolving field.